The ASF Scientific Advisory Committee identified the following areas of unmet need in AS research. Priority will be given to the following topics:
Projects studying or correcting the heterozygous effect of non-UBE3A genes in deletion.
Projects studying the potential results of increasing UBE3A after therapies or for some subtypes of AS.
Projects studying delivery of therapies and potential for improvement.
Symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.
Proposals that do not address these topics are still welcome and will be given full consideration.